STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4/A] ANAPTYSBIO, INC Amended Insider Trading Activity

AnaptysBio (NASDAQ: ANAB) CEO disposes of 11,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities. He returned 11,000 employee stock options, each exercisable for one share of common stock at $31.12 per share, to the issuer. The filing notes the option was fully vested and exercisable, and this was a non-market disposition back to the company rather than an open-market trade.

Positive

  • None.

Negative

  • None.

Insights

CEO returns 11,000 vested options to issuer in a non-market move.

President and CEO Daniel Faga reported a Disposition to issuer of 11,000 fully vested employee stock options with a $31.12 exercise price, linked to an equal number of common shares. No market trade price is shown, indicating this is an administrative equity change.

The filing shows one derivative transaction and no remaining derivative positions in this line item, suggesting a cleanup of part of his option awards rather than a purchase or sale of common stock. With no broader holding data in this excerpt, the transaction reads as routine and has limited informational value for shareholders.

Insider Faga Daniel
Role President, CEO
Type Security Shares Price Value
Disposition Employee Stock Option (right to buy) 11,000 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 11,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options disposed 11,000 options Employee stock options disposed to issuer
Underlying shares 11,000 shares Common stock underlying disposed options
Exercise price $31.12 per share Strike price of the employee stock options
Expiration date November 25, 2031 Option expiration for disposed grant
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
Disposition to issuer financial
"transaction_action: issuer disposition; transaction_code_description: Disposition to issuer"
fully vested and exercisable financial
"footnote: The stock option is fully vested and exercisable."
derivative transaction financial
"transactionSummary notes a derivativeTransactionCount of 1"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Faga Daniel
(Last)(First)(Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President, CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
04/22/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$31.1204/20/2026D11,000 (1)11/25/2031Common Stock11,000$011,000D
Explanation of Responses:
1. The stock option is fully vested and exercisable.
Remarks:
This amendment to Form 4, filed on April 23, 2026, updates the number of stock options to 11,000 shares of the Issuer's common stock.
/s/ Dan Faga04/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ANAPTYSBIO (ANAB) report for Daniel Faga?

ANAPTYSBIO reported that President and CEO Daniel Faga disposed of 11,000 employee stock options back to the issuer. These options were fully vested and exercisable and related to 11,000 shares of common stock at a $31.12 exercise price per share.

Was the ANAB CEO’s Form 4/A transaction a market sale of shares?

No. The Form 4/A shows a “Disposition to issuer” of 11,000 employee stock options, not an open-market sale of common stock. The transaction price per option is reported as $0.00, indicating a non-market, administrative return of options to the company.

What were the key terms of the ANAB stock options Daniel Faga disposed of?

The disposed instruments were employee stock options to buy 11,000 ANAPTYSBIO common shares at an exercise price of $31.12 per share. A footnote states the stock option was fully vested and exercisable, with an expiration date of November 25, 2031.

How many derivative transactions does this ANAB Form 4/A amendment include?

The filing includes one derivative transaction: a disposition to the issuer of 11,000 employee stock options linked to 11,000 common shares. The transaction summary classifies this as a single derivative transaction with a dispose direction and no offsetting purchases or exercises.

Does the ANAB Form 4/A indicate ongoing derivative holdings for the CEO?

In this excerpt, the derivative summary is empty after the reported disposition, and no other derivative positions are listed. That suggests no remaining positions of this specific option award are shown here, though it does not rule out other awards outside this excerpt.